Related Experiment Video
Updated: Mar 25, 2026
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications
1Institute of Endocrinology, Diabetes, and Metabolism, Rambam Health Care Campus, Haifa, Israel.
Abstract:
Differentiated thyroid cancer (DTC) is a common and diverse endocrine malignancy. In most patients DTC results in an indolent and curable disease. Nevertheless, disease recurrence rates are relatively high (10%-30%), while 5% of the patients are resistant to conventional treatment and some of these patients are incurable. Over the past 20 years much progress has been made in identifying genetic changes that occur in DTC. In addition, studies aimed to understand the role of these genetic changes in tumorigenesis and their effects on the clinical characteristics of the disease have been conducted. The accrued knowledge has set the stage for development of genetic tests aimed to identify these changes in samples obtained from DTC patients and use this information in the clinical decision process. This paper reviews genetic changes that were identified in DTC, and how the emerging data obtained by genetic testing are currently used to gain key information on the diagnosis, risk stratification, and personalized care of DTC patients.
Insights
Genetic testing advances personalized care for differentiated thyroid cancer (DTC). Understanding genetic changes in DTC aids diagnosis, risk stratification, and treatment, improving outcomes for this common endocrine malignancy.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Background:
- Differentiated thyroid cancer (DTC) is a common endocrine malignancy with high recurrence rates (10%-30%) and some incurable cases resistant to conventional treatment.
- Significant progress has been made in identifying genetic alterations in DTC over the past two decades.
- Research has focused on the role of these genetic changes in tumorigenesis and their impact on clinical presentation.
Purpose of the Study:
- To review the genetic alterations identified in differentiated thyroid cancer.
- To discuss how genetic testing data is utilized for diagnosis, risk stratification, and personalized care of DTC patients.
- To highlight the clinical utility of emerging genetic insights in managing DTC.
Main Methods:
- Review of genetic changes identified in differentiated thyroid cancer.
- Analysis of studies investigating the role of genetic alterations in DTC tumorigenesis and clinical characteristics.
- Examination of the application of genetic testing in clinical decision-making for DTC patients.
Main Results:
- Numerous genetic changes have been identified in differentiated thyroid cancer.
- This knowledge has facilitated the development of genetic tests for DTC.
- Emerging data from genetic testing provide key information for DTC diagnosis, risk assessment, and tailored treatment strategies.
Conclusions:
- Genetic alterations play a crucial role in the development and progression of differentiated thyroid cancer.
- Genetic testing is becoming integral to the clinical management of DTC, enabling more precise diagnosis and risk stratification.
- The integration of genetic information supports personalized care approaches for patients with differentiated thyroid cancer.
